AGC Biologics acquires AstraZeneca commercial biomanufacturing facility

2 Jun 2020

The Boulder, Colorado, USA facility will increase global capacity and extend manufacturing scale.

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has purchased a state-of-the-art commercial manufacturing facility — formerly owned by AstraZeneca — in Boulder, Colorado, USA.

AGC Biologics acquires AstraZeneca commercial biomanufacturing facility

The large-scale biopharmaceutical manufacturing facility houses two 20,000-L (total volume) stainless steel mammalian cell bioreactors. It also has more than 20 acres with multiple opportunities for future expansions, including space for up to four more 20,000-L bioreactors. The automated facility is particularly well suited for high volume commercial production and high titer antibody processes.

AGC Biologics is rapidly expanding its customer portfolio, including a higher ratio of late-phase and commercial projects, as well as advancing current projects into the commercial phase. This addition to their facility network will enable the company to support a wider range of commercial demand.

In addition to this facility acquisition, AGC Biologics is completing major facility expansion projects at its Seattle, Copenhagen and Chiba facilities in 2020 and early 2021. The facility is expected to begin full-scale operations and manufacturing by April 2021.

Read More

Related news

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

7 Jul 2020

The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.

Read more 
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

7 Jul 2020

The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.

Read more 
Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

6 Jul 2020

The transaction will more than double Croda’s R&D capability in drug delivery.

Read more 
Rentschler Biopharma and Vetter team up to simplify processes

Rentschler Biopharma and Vetter team up to simplify processes

6 Jul 2020

Companies agree that the key to tackling drug development complexity is collaboration.

Read more 
Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility

Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility

6 Jul 2020

An investment of $3.6 million will cover the installation of a new production line to keep pace with continued growth in commercial-scale API manufacturing.

Read more 
iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
Catalent expands beauty and plant-based consumer health softgel capabilities

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more